Investment Rating - The report maintains an "Accumulate" rating for the company [7]. Core Views - The company is expected to achieve revenue of 6.7 billion RMB and a net profit attributable to the parent company of 1.739 billion RMB in 2025, reflecting year-on-year growth of 9%, 12%, and 14% respectively [1]. - The company plans to distribute approximately 1.74 billion RMB in dividends, which accounts for 100% of the net profit attributable to the parent company [1]. - The report highlights the company's focus on "four restructurings" to drive continuous sales and profit growth, with an emphasis on expanding the Ejiao category and developing new health consumer products [1][3]. Revenue Growth - The Ejiao series is projected to grow by 12% in revenue for 2025, with a gross margin increase of 1.2 percentage points to 74.8% [2]. - Specific product growth estimates include a 5-10% increase for Ejiao blocks, approximately 15% for Ejiao syrup, flat growth for Ejiao cakes, and over 40% for Ejiao powder [2]. - The company anticipates maintaining double-digit revenue growth for the Ejiao series from 2026 to 2027, driven by consumption recovery and product expansion [2]. Strategic Developments - The company is accelerating its expansion in the tonic product category, forming strategic partnerships for various products including deer antler and meat corydalis [3]. - A significant investment of approximately 1.5 billion RMB is planned for the construction of a health consumer products industrial park, indicating a strategic shift towards health consumer products [3]. Financial Performance - The report notes a decrease in accounts receivable and an increase in operating cash flow, with a net operating cash flow of 2.29 billion RMB in 2025, exceeding net profit due to a decline in accounts receivable [4]. - The sales, management, and R&D expense ratios for 2025 are projected at 32.0%, 7.2%, and 4.1% respectively, indicating ongoing optimization of sales expenses [4]. Earnings Forecast - The company’s net profit attributable to the parent company is forecasted to be 1.999 billion RMB in 2026, with a growth rate of 14.97% [11]. - The report adjusts the revenue forecast upwards due to higher-than-expected Ejiao sales, while slightly lowering profit forecasts for 2026 and 2027 [5]. - The target price for the company is set at 77.57 RMB, based on a PE ratio of 25x for 2026 [5].

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of 83.65 RMB [7][5]. Core Views - The company has shown resilient growth despite industry pressures, with revenue and net profit for the first three quarters of 2025 reaching 47.7 billion RMB and 12.7 billion RMB, respectively, reflecting year-on-year growth of 4% and 11% [1]. - The company is expected to continue its double-digit growth in the Ejiao series, driven by online channel expansion and consumer recovery [2]. - The company is accelerating its expansion in the tonic product category, with strategic partnerships in various product lines, aiming to transition from a leader in Ejiao to a leader in comprehensive tonics during the 14th Five-Year Plan period [3]. Financial Performance - The sales, management, and R&D expense ratios for the first three quarters of 2025 are 35.2%, 6.1%, and 3.0%, respectively, indicating a continuous optimization in sales expenses and an increase in R&D expenses due to strategic investments [4]. - The operating cash flow for the first three quarters of 2025 is 13.1 billion RMB, slightly higher than net profit, indicating strong cash flow management [4]. Earnings Forecast - The report projects net profits for 2025, 2026, and 2027 to be 18.0 billion RMB, 20.5 billion RMB, and 23.2 billion RMB, respectively, with year-on-year growth rates of 15%, 14%, and 13% [5][11].

Investment Rating - The report maintains a "Recommendation" rating for Dong'e Ejiao, with a target price of 72.5 yuan [2][8]. Core Insights - In Q1 2025, Dong'e Ejiao reported revenue of 1.72 billion yuan, representing an 18.2% year-over-year increase, and a net profit attributable to shareholders of 430 million yuan, up 20.2% year-over-year [2][4]. - The company emphasizes the resilience of its operations despite short-term cash flow fluctuations, with a focus on improving financial metrics such as cash flow and accounts receivable [2][8]. - The company is expected to achieve double-digit revenue growth in its Ejiao series due to channel expansion and increased online and offline sales activities [8]. Financial Performance Summary - Total revenue projections for Dong'e Ejiao are as follows: - 2024: 5.921 billion yuan - 2025: 6.919 billion yuan (16.9% growth) - 2026: 8.022 billion yuan (15.9% growth) - 2027: 9.191 billion yuan (14.6% growth) [4][9] - Net profit attributable to shareholders is projected to grow as follows: - 2024: 1.557 billion yuan - 2025: 1.869 billion yuan (20.0% growth) - 2026: 2.205 billion yuan (18.0% growth) - 2027: 2.602 billion yuan (18.0% growth) [4][9]. - The company maintains a low inventory level and a stable contract liability of 590 million yuan, indicating sufficient orders [8]. Strategic Focus - Dong'e Ejiao is committed to its "1238" strategy, aiming to expand its core Ejiao business and explore new growth areas such as male health products [8]. - The company has a high dividend payout ratio of 99.7% for 2024, indicating strong cash reserves and a commitment to shareholder returns [8]. - The management is focused on enhancing operational quality through comprehensive budget management and performance assessments [8].